Measurement of Equilibrium Angiotensin II in the Diagnosis of Primary Aldosteronism

Many medications (including most antihypertensives) and physiological factors affect the aldosterone/renin ratio (ARR) when screening for primary aldosteronism (PA). We sought to validate a novel equilibrium angiotensin II (eqAngII) assay and compare correlations between the aldosterone/angiotensin...

Full description

Saved in:
Bibliographic Details
Published in:Clinical chemistry (Baltimore, Md.) Md.), 2020-03, Vol.66 (3), p.483-492
Main Authors: Guo, Zeng, Poglitsch, Marko, McWhinney, Brett C, Ungerer, Jacobus P J, Ahmed, Ashraf H, Gordon, Richard D, Wolley, Martin, Stowasser, Michael
Format: Article
Language:English
Subjects:
Aldosterone
Analysis
Angiotensin
Angiotensin II
Antihypertensives
Assaying
Biosynthesis
Consistency
Diagnosis
Diagnostic systems
Endocrine disorders
Enzymes
Equilibrium
Ethylenediaminetetraacetic acid
Fludrocortisone
Hyperaldosteronism
Hypertension
Low concentrations
Measurement
Medical diagnosis
Peptides
Physiological effects
Physiological factors
Physiology
Posture
Renin
Sensitivity
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many medications (including most antihypertensives) and physiological factors affect the aldosterone/renin ratio (ARR) when screening for primary aldosteronism (PA). We sought to validate a novel equilibrium angiotensin II (eqAngII) assay and compare correlations between the aldosterone/angiotensin II ratio (AA2R) and the current ARR under conditions affecting the renin-angiotensin system. Among 78 patients recruited, PA was excluded in 22 and confirmed in 56 by fludrocortisone suppression testing (FST). Peripheral levels of eqAngII, plasma renin activity (PRA) and direct renin concentration (DRC) were measured. EqAngII showed good consistency with DRC and PRA independent of PA diagnosis, posture, and fludrocortisone administration. EqAngII showed close (P 
ISSN:0009-9147
1530-8561
DOI:10.1093/clinchem/hvaa001